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Calnexin, an ER-induced protein, is a 
prognostic marker and potential therapeutic 
target in colorectal cancer
Deborah Ryan1,2, Steven Carberry1, Áine C. Murphy1, Andreas U. Lindner1, Joanna Fay3, Suzanne Hector1, 
Niamh McCawley1,2, Orna Bacon1,2, Caoimhin G. Concannon1,2, Elaine W. Kay3, Deborah A. McNamara2 
and Jochen H. M. Prehn1*
Abstract 
Background: Colorectal cancer (CRC) is a leading cause of cancer mortality in the Western world and commonly 
treated with genotoxic chemotherapy. Stress in the endoplasmic reticulum (ER) was implicated to contribute to 
chemotherapeutic resistance. Hence, ER stress related protein may be of prognostic or therapeutic significance.
Methods: The expression levels of ER stress proteins calnexin, calreticulin, GRP78 and GRP94 were determined in 
n = 23 Stage II and III colon cancer fresh frozen tumour and matched normal tissue samples. Data were validated in a 
cohort of n = 11 rectal cancer patients treated with radiochemotherapy in the neoadjuvant setting. The calnexin gene 
was silenced using siRNA in HCT116 cells.
Results: There were no increased levels of ER stress proteins in tumour compared to matched normal tissue samples 
in Stage II or III CRC. However, increased calnexin protein levels were predictive of poor clinical outcome in the patient 
cohort. Data were validated in the rectal cancer cohort treated in the neoadjuvant setting. Calnexin gene-silencing 
significantly reduced cell survival and increased cancer cell susceptibility to 5FU chemotherapy.
Conclusion: Increased tumour protein levels of calnexin may be of prognostic significance in CRC, and calnexin may 
represent a potential target for future therapies.
Keywords: Colorectal cancer, ER Stress, Calnexin, GRP78, GRP94, UPR (unfolded protein response)
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Background
Colorectal cancer is one of the most common cancers 
among men and women in the Western world and the 
third leading cause of cancer-related mortality. Current 
treatment options for patients are dependent on dis-
ease stage at diagnosis but include surgery and adjuvant 
chemotherapy [1]. The most common chemotherapy 
regime currently used in the treatment of Stage II and III 
colorectal cancer is 5–fluorouracil (5FU), often in com-
bination with oxaliplatin or irinotecan depending on a 
patients’ clinical status [2, 3]. For patients with Stage II 
node negative disease, it is unclear if adjuvant therapy 
will be beneficial, as the majority of these patients will 
respond to surgery alone, with only a small subset of 
patients deriving benefit from adjuvant chemotherapy 
[4]. Adjuvant 5FU-based chemotherapy in stage III dis-
ease benefits c. 15–20 % of patients, yet the majority of 
patients will relapse or develop distant metastases within 
5  years following surgery [5]. It is therefore important 
that we improve our ability to identify patients who will 
benefit from adjuvant chemotherapies and to discover 
novel drug targets for those patients resistant to current 
chemotherapeutics.
The endoplasmic reticulum (ER) is an essential cellular 
organelle responsible for the synthesis; maturation and 
trafficking of a wide range of proteins and is a critical site 
Open Access
Journal of 
Translational Medicine
*Correspondence:  prehn@rcsi.ie 
1 Department of Physiology and Medical Physics, Centre for Systems 
Medicine, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, 
Dublin 2, Ireland
Full list of author information is available at the end of the article
Page 2 of 10Ryan et al. J Transl Med  (2016) 14:196 
for calcium homeostasis. Due to its central role in pro-
tein folding and quality control, the ability of the ER to 
adapt to adverse conditions is essential to the survival 
of a cell [6, 7]. ER stress is triggered by the accumula-
tion of unfolded or misfolded proteins in the ER and can 
result from an increased demand for protein synthesis, 
accumulation of mutant proteins, or from a pathophysi-
ological interference with regular ER functions such as 
maintenance of Ca2+ homeostasis, hypoxia/ischemia or 
oxidative stress [8]. ER stress triggers the cell’s unfolded 
protein response (UPR), which alters transcriptional and 
translational programmes within the cell. The goal of the 
UPR is to protect the cell from ER stress by decreasing 
the number of proteins translocated into the ER lumen, 
by increasing retrotranslocation and augmenting the pro-
tein folding capacity of the ER [7]. ER stress induces a 
number of different proteins such as chaperones from the 
heat shock protein family including GRP78 and GRP94; 
Ca2+ binding chaperone lectins such as calnexin and cal-
reticulin; and substrate specific chaperones [7].
Somatic gene mutations as well as ischemic conditions 
may trigger ER stress and elicit the UPR in tumour cells. 
Rapid growth of tumours can lead to inadequate vascu-
larisation resulting in decreased levels of oxygen, nutri-
ents and glucose as well as altering intracellular calcium 
levels. In highly oncogenic tumours, protein overproduc-
tion or mutations found within tumour cells may cause 
mutant protein accumulation leading to ER stress [6, 9]. 
ER stress proteins have been shown to be upregulated in 
a number of tumour types including breast, lung, liver 
and prostate tumours and it has been suggested that 
these altered levels of ER stress proteins are essential for 
the survival of cancer cells in the inhospitable tumour 
microenvironment [7, 10, 11]. Thus, in this study we 
examined whether the ER stress proteins GRP78, GRP94, 
calnexin and calreticulin are differentially expressed in 
colorectal tumours compared to matched normal tissue 
and determined if there was any association between the 
expression of ER stress proteins and disease stage or clin-
ical outcome in our CRC patient cohort.
Methods
Patients
Patient tissue samples were collected and stored in 
the APOCOLON colorectal tissue biobank at Beau-
mont Hospital (Dublin, Ireland). Informed consent was 
received from all patients and ethical approval for use 
of the stored material was granted by Beaumont Hos-
pital Ethics (Medical Research; 08/62, 11/09 and 16/20) 
Committee. Snap-frozen colorectal tumour and matched 
normal tissue from surgical resections of 23 Stage II 
(n = 8) and III (n = 15) colorectal cancer patients were 
prospectively collected. Fourteen of the stage III patients 
and one stage II patient received adjuvant chemotherapy 
with 10 receiving 5FU and leucovorin, 3 receiving 5FU, 
leucovorin and oxaliplatin while 1 patient received 5FU, 
leucovorin and irinotecan, and 1 patient received 5FU, 
leucovorin, irinotecan and bevacizumab. In 15 cases, 
patients had a good outcome which was defined as no 
mortality or disease recurrence within the 4-year follow-
up period while 8 cases had a poor outcome, specifically, 
disease recurrence or death from disease within that 
timeframe.
Clinical follow-up was obtained for all patients and 
patient characteristics are summarised in Table 1.
Validation cohort (neoadjuvant setting)
Pre-treatment biopsies were also obtained from a sepa-
rate cohort of rectal cancer patients by colonoscopy or 
rigid sigmoidoscopy and stored from the Departments 
of Surgery, and Pathology, Beaumont Hospital, Dublin, 
Ireland. Following treatment, surgical resections of these 
patients was obtained. Ethical approval was obtained by 
the Beaumont Hospital Ethics (Medical Research; 08/62, 
11/09 and 16/20) Committee, and informed consent was 
Table 1 Details of  the disease stage, chemotherapy treat-
ment and  disease outcome of  the 23 patients within  the 
study
5FU 5-fluorouracil; Fol Fluorouracil; Irin irinotecan; Leu leucovorin; Oxal 
oxaliplatin; None no chemotherapy received
Patient Stage Received chemotherapy Outcome
1 II None Good
2 II None Good
3 II None Poor
4 II None Good
5 II None Good
6 II None Poor
7 II None Poor
8 II 5FU + Leu Good
9 III None Good
10 III Fol + 5FU + Oxal + Irin Poor
11 III 5FU + Leu Good
12 III 5FU + Leu Good
13 III 5FU + Leu Poor
14 III 5FU + Leu Good
15 III Fol + 5FU + Oxal Good
16 III Fol + 5FU + Oxal Poor
17 III 5FU + Leu Good
18 III Fol + 5FU + Oxal Poor
19 III 5FU + Leu Good
20 III 5FU + Leu Good
21 III 5FU + Leu + Irin + bevacizumab Poor
22 III 5FU + Leu Good
23 III 5FU + Leu Good
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obtained from all patients. Resections were evaluated 
to ensure consistent quality and tumour presence by an 
experienced pathologist. Clinical follow-up and response 
to neoadjuvant radio chemotherapy was obtained for all 
patients and patient characteristics are summarised in 
Table 2. After neoadjuvant chemo-radiotherapy, patients’ 
response to therapy was determined using RCPath crite-
ria. Good responders were identified as patients show-
ing complete tumour progression (RCPathA). Poor 
responders were identified as patients showing par-
tial or no marked tumour regression (RCPathB and C, 
respectively).
Western blotting
For clinical samples, tissue was lysed in ice-cold tissue 
lysis buffer [50  mmol/L HEPES (pH 7.5), 150  mmol/L 
NaCl, 5 mmol/L Na-EDTA] and protease inhibitor cock-
tail (Calbiochem, Hampshire UK) followed by mechani-
cal homogenization on ice. Following centrifugation 
(14,000×g for 10  min), supernatant was collected and 
stored at −80 °C until further use. For the cell line experi-
ments, cells were trypsinised and cell pellets collected 
for each experiment. Cell pellets were then lysed with 
SDS lysis buffer (2 % SDS, 10 % glycerol, 67.5 mM Tris/
Cl− pH 6.8) and protease inhibitor cocktail. The samples 
were then heated to 95  °C while shaking (600  rpm for 
20  min) following which the supernatant was collected 
and stored at −80  °C until further use. Protein concen-
tration was measured using micro BCA (bicinchoninic 
acid) assay (Pierce, Rockford, IL). Total protein (20  µg) 
was resolved using SDS–PAGE, transferred to nitrocel-
lulose membranes and blocked in TBS-T/5  % milk for 
1  h. Membranes were incubated in primary antibody, 
calnexin (1:1000, rabbit polyclonal), calreticulin (1:1000, 
mouse monoclonal) and KDEL (1:500, mouse mono-
clonal) (Enzo Life Sciences, Exeter, UK) overnight at 
4  °C, washed in TBS-T and incubated in the appropri-
ate horseradish peroxidase secondary antibody at room 
temperature for 1 h. The KDEL antibody used binds the 
amino acid sequence Lys-Asp-Glu-Leu (KDEL) present 
at the carboxy-terminus of GRP78 and GRP94 thus this 
antibody detects both GRP78 and GRP94. Detection of 
protein bands was carried out using chemiluminescence 
(EMD Millipore, Billerica, MA, USA) on a LAS-3000 
Imager (FUJIFILM UK Ltd. Systems, Bedford UK). Den-
sitometry on each band was carried out using ImageJ 
software and normalized to Actin (1:5000 mouse mono-
clonal, Sigma Aldrich, Dublin, Ireland) loading control. 
Actin normalized intensities were then used to determine 
tumor to matched normal ratios for each patient.
Calnexin gene silencing in HCT116 cells
HCT116 colon cancer cells were transfected with cal-
nexin siRNA and control scramble siRNA (Santa Cruz 
Biotechnology, Dallas, TX, USA). The cells were seeded 
on 6-well tissue culture plates (2  ×  105  cells/well) and 
transfected after 24 h. After a further 24 h, cells were har-
vested to confirm knockdown of calnexin expression by 
western blot analysis.
Flow cytometry
Following transfection of HCT116 cells with calnexin or 
control scramble siRNA for 24  h and subsequent treat-
ment with 5FU or vehicle for 48 h, cells were harvested 
and the induction of cell death was assessed by Annexin 
V and PI staining using flow cytometry. Cells were incu-
bated at room temperature in binding buffer (10  mM 
HEPES, 135 mM NaCl, 5 mM CaCl2) which contained an 
Annexin V-FITC conjugate (1 μl/ml; BioVision, Mountain 
View, CA, USA) and propidium iodide (PI; 1 μl/ml, Bio-
Vision) for 15  min. Cells were counted in a Cyflow ML 
16 flow cytometer (Partec, Münster, Germany). Excita-
tion of Annexin V-FITC was done with a 488  nm laser 
and fluorescence emission was collected in the FL1 chan-
nel through a 520 nm band pass filter. PI was excited with 
a 488 nm laser and fluorescence emission was collected 
in the FL3 channel through a 620  nm long pass filter. 
1  ×  104 gated cells were acquired for each sample and 
analyzed using the Flowmax software (Partec).
Clonogenic survival assay
HCT116 cells were transfected with calnexin or control 
scramble siRNA for 24 h and then plated for a clonogenic 
survival assay. Transfected cells were seeded on a 6-well 
plate (1 × 103 cells/well) in medium (3 ml) and incubated 
at 37 °C for 5 days. After 5 days, the medium was replaced 
with fresh medium and cells were incubated for a further 
Table 2 Details of  the disease stage, chemotherapy treat-
ment and disease outcome of the 11 rectal cancer patients 
of our validation cohort
5FU 5-fluorouracil; 50.4/28, total amount of 50.4 Gy radiotherapy in 28 fractions
Patient Stage Neo-adjuvant therpay RCPATH Outcome
1 III 50.4/28 + 5FU A Good
2 III 54.0/30 + 5FU A Good
3 III 50.4/28 + 5FU A Good
4 II 50.4/28 + 5FU A Good
5 III 50.4/28 + 5FU B Poor
6 III 50.4/28 + 5FU B Poor
7 III 50.4/28 + 5FU B Poor
8 III 50.4/28 + 5FU B Poor
9 III 50.4/28 + 5FU C Poor
10 III 50.4/28 + 5FU C Poor
11 II 50.4/28 + 5FU C Poor
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9  days at which time medium was removed and clono-
genic reagent (2 ml; 50 % ethanol, 0.25 % 1, 9 dimethlyene 
blue) was added to each well and incubated at room tem-
perature for 45 min. The cells were then washed with PBS 
and the number of colonies was counted.
Immunohistochemistry
Tissue sections were cut at 3 μm on to Leica Microsys-
tems Plus slides and were baked over night at 37 °C prior 
to immunostaining. All staining was performed on a 
Leica Bond III automated immunostainer from Leica 
Biosystems, Newcastle, UK. Sections were loaded onto 
the system and the relevant programme was selected. 
The Bond-III system dewaxed slides and then carried out 
a 20  min pre-treatment with BOND Epitope Retrieval 
Solution I (Cat. no. AR9961). Antibodies were chosen 
based on their suitability for use on FFPE tissue and opti-
mised. Primary antibodies were diluted in Bond Primary 
Antibody Diluent (Cat. no. AR9352)—1:400 diluted rab-
bit polyclonal anti-Calnexin (ADI-SPA-860, Enzo Life 
Sciences, Exeter, UK) and were added to the sections for 
20  min. Detection and visualisation of stained cells was 
achieved using the Bond Polymer Refine Detection Kit 
(Cat. no. DS9800), using diaminobenzidine tetrachloride 
(DAB) as the chromagen. Tissues were counterstained 
with haematoxylin and were cover slipped. Negative 
controls for rabbit antibody (Negative Control Rabbit 
Immunoglobulin fraction of serum from non-immunized 
rabbits, IS600, Dako) were included and no staining was 
observed in these controls.
Statistical analysis
All results from the patient samples and cell line work 
were analysed using GraphPad InStat software. The 
expression of individual proteins in tumour and matched 
normal samples was examined with two-sided Wilcoxon 
signed-rank test for related variables. The expression of 
the tumour to normal ratios was calculated using Mann–
Whitney U test for independent samples. In  vitro data 
were analysed by basic t tests and one-way ANOVA with 
Student–Newman–Keuls post hoc test where appropri-
ate. Results were considered significant when the p-value 
was <0.05.
Results
Expression of ER Stress proteins in stage II and stage III 
colorectal cancer patient samples
The activation of the UPR in response to ER stress has 
the potential to allow cancer cells to survive adverse con-
ditions that may otherwise lead to apoptosis. In order 
to examine the potential role of ER stress in colorectal 
cancer we determined the expression of the ER stress 
proteins calreticulin (Fig.  1b), calnexin (Fig.  1c), GRP78 
(Fig.  1d) and GRP94 (Fig.  1e) in colorectal tumour and 
matched normal tissue from patients with Stage II (n = 8) 
and Stage III (n = 15) disease (Additional file 1: Table S1). 
Sample images of the Western blots of the ER stress pro-
teins can be seen in Fig. 1a. A two-sided Wilcoxon signed 
rank test analysis of the expression of the ER stress pro-
teins in the tumour samples and matched normal tissue 
established that there was no differential expression of 
the proteins between tumour and normal tissue (Fig. 1b, 
c, d, e). Furthermore, the levels of GRP78 and GRP94 
were very low across the total patient cohort (Fig. 1d, e 
respectively). Additional file  2: Figure S1 provides an 
additional analysis with paired samples highlighted.
Expression of ER stress proteins as a predictor of disease 
stage
Since there was no differential expression of ER stress 
proteins between tumour and normal tissue in our CRC 
patient samples, we next assessed if the ratio of ER stress 
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Fig. 1 Levels of ER stress proteins in a cohort of stage II and stage 
III CRC patients. Sample western blots showing the levels of the ER 
stress proteins GRP94, GRP78, calnexin and calreticulin in colorectal 
tumour (T) and matched normal (N) colonic tissue (a). Scatter plots 
depicting expression of calreticulin (b), calnexin (c), GRP78 (d) and 
GRP94 (e) in colorectal tumour and matched normal tissue. Differ-
ences between tumour and matched normal tissue were assessed by 
Wilcoxon signed rank test. The mean, median and standard deviation 
STD were stated below the panels
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protein expression in tumour compared to normal tis-
sue could be predictive of disease stage. We preferred to 
perform a tumour/normal ratio analysis to better control 
for potential differences in sample acquisition times and 
sample preparations among individually collected patient 
samples. Patient samples were subdivided by disease 
stage, stage II and stage III, and the ratio of calreticulin 
(Fig. 2a), calnexin (Fig. 2b), GRP78 (Fig. 2c) and GRP94 
(Fig.  2d) in tumour versus normal tissue was evaluated. 
This analysis determined that there was no statistically 
significant difference between the ratios of ER stress pro-
tein expression in tumour versus normal tissue in sam-
ples from patients with Stage II CRC compared with 
samples from patients with Stage III CRC. Thus, the 
tumour/normal ratios of ER stress proteins are not pre-
dictive of disease stage. We likewise found no differences 
when comparing tumour and matched normal samples 
independently (Additional file 3: Figure S2).
Expression of ER stress proteins as predictors of clinical 
outcome
Since ER stress may alter tumour growth and chemo-
sensitivity of tumour cells, it may also influence clini-
cal outcomes and patient survival. Therefore, we next 
examined whether the expression of ER stress associ-
ated proteins in tumour tissue compared to normal 
tissue was associated with clinical outcome. Patient 
samples were divided based on the clinical outcome 
of the patients with good outcome being defined as no 
mortality or disease recurrence within the 4 year follow-
up period while poor outcome was defined as disease 
recurrence or death from disease within that timeframe. 
The tumour/normal ratios of calnexin (p  =  0.0055; 
Fig.  3b) were significantly increased in samples from 
patients who had poor clinical outcome. No significant 
differences in the tumour/normal ratios of calreticu-
lin (Fig. 3a), GRP78 (Fig. 3c) and GRP94 (Fig. 3d) were 
detected. We likewise found elevated protein levels of 
calnexin in tumour (p =  0.0030) but not matched nor-
mal tissue of patients with poor outcome when compar-
ing tumour and matched normal samples independently 
(Additional file  4: Figure S3). In a separate analysis, we 
analysed only those patients who received 5FU based 
adjuvant chemotherapy. The tumour/normal ratios of 
calnexin (p = 0.0093; Additional file 5: Figure S4B) were 
significantly increased in samples from patients who 
received chemotherapy and had poor clinical outcome. 
No significant differences in the expression of calreticu-
lin, GRP78 and GRP94 in tumour compared to matched 
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normal tissue were detected in samples from patients 
with good or poor outcome who received chemotherapy 
(Additional file 5: Figure S4A, C, D).
We also explored whether there were potential dif-
ferences in the subcellular localization of calnexin in 
patients with good or poor outcome, and performed an 
immunohistochemical analysis of in good and in poor 
outcome cases. However, we observed little variation in 
the subcellular localization of calnexin in good and poor 
responders, with cytoplasmic, punctuate calnexin stain-
ing in all tumor cells (Fig. 4).
Calnexin is a prognostic biomarker in rectal cancer patients 
treated in the neoadjuvant setting
To validate our findings, pre-treatment biopsy tumour 
tissue samples were obtained at colonoscopy or rigid 
sigmoidoscopy (Table  1) from 11 rectal cancer patients. 
Using quantitative Western blotting, the expression lev-
els of calnexin in tumour biopsy tissue were determined 
in all 11 patients (Additional file 1: Table S2). After neo-
adjuvant chemoradiotherapy (50.4/28  +  5FU), patients’ 
response to therapy was determined on surgical resected 
tissue. Patients were either classified as good outcome 
(RCPath A; complete tumour regression) or bas outcome 
[RCPath B (partial tumour regression) or RCPath C (no 
marked tumour regression)].
We found statistically significant differences of the 
Calnexin level between the RCPaths (Kruskal–Wallis 
test p = 0.0295). After adjustment for multi-comparison 
(Bonferroni correction, α = 0.0125), Calnexin levels were 
significant up-regulated in poor responders (RCPath B 
or C), compared to good responders (RCPath A; Mann–
Whitney U test p = 0.0286) (Fig. 5).
The effect of calnexin knockdown on clonogenic survival 
and the induction of cell death by 5FU in HCT116 cells
To determine a role for calnexin in colorectal cancer 
cell survival and 5FU-induced cell death, we silenced 
calnexin gene expression in HCT116 cells using siRNA-
mediated gene silencing. We first ascertained a success-
ful reduction of calnexin protein levels in HCT116 cells 
24  h post calnexin siRNA transfection as determined 
by Western blot analysis (Fig. 6a). A clonogenic survival 
assay was utilised to assess the ability of HCT116 cells to 
survive and proliferate following calnexin gene silencing. 
Gene silencing of calnexin significantly decreased clono-
genic survival (p = 0.0021, Fig. 6b).
Since calnexin expression was significantly elevated 
in patients with poor outcome who received 5FU-based 
chemotherapy, we next examined the effect of calnexin 
knockdown on chemosensitivity in HCT116 cells. Follow-
ing transfection with calnexin siRNA for 24 h, HCT116 
cells were treated with 5FU (20 µg/ml) for 48 h and the 
induction of cell death was determined by Annexin V 
and PI staining using flow cytometry. The percentage 
of Annexin V+ cells, indicating apoptosis, was signifi-
cantly increased when HCT116 cells transfected with 
calnexin siRNA and treated with 5FU were compared 
with HCT116 cells transfected with control siRNA and 
treated with 5FU [Fig. 6c, *p < 0.05 versus HCT116 cells 
transfected with control siRNA and treated with 5FU]. 
Treatment with 5FU significantly increased the percent-
age of PI+ cells in both control and calnexin siRNA trans-
fected HCT116 cells with no significant effect of calnexin 
knockdown observed [Fig. 6d, **p < 0.01 versus HCT116 
cells transfected with control siRNA and treated with 
vehicle; ###p  <  0.001 versus HCT116 cells transfected 
Stage II, poor outcomeStage II, good outcome
100µm100µm
Fig. 4 Immunohistochemical analysis of calnexin expression in CRC. Immunohistochemical staining of paraffin-embedded human colorectal can-
cer patient tissue using anti-calnexin polyclonal antibody. Tissue section on the left represents one CRC stage II good responder and tissue section 
on the right shows a CRC stage II poor responder. Calnexin immunostaining localised to the cytoplasm in both good and poor responsers. Images 
are representative of the n = 15 and n = 8 good and poor responders analysed by immunohistochemistry. Hematoxylin staining was performed to 
visualise nuclei (blue colour). Scale bar corresponds to 100 µm
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with calnexin siRNA and treated with vehicle]. While 
treatment of control siRNA transfected HCT116 cells 
with 5FU did not significantly increase the percentage 
of Annexin+PI+ cells, knockdown of calnexin synergised 
with 5FU treatment to significantly enhance the percent-
age of HCT116 Annexin+PI+ cells [Fig.  6e, **p  <  0.01 
versus HCT116 cells transfected with control siRNA and 
treated with 5FU].
Discussion
The significant findings of this study identify the ER cal-
cium binding chaperone calnexin as promising prognos-
tic marker and therapeutic target in colorectal cancer. We 
have demonstrated that Calnexin levels correlated with 
clinical response in the total population of stage 2 and 
3 CRC patients and in patients who received 5FU-based 
adjuvant chemotherapy. These findings were validated in 
rectal cancer patients treated with chemoradiation ther-
apy in the neoadjuvant setting. Furthermore, we establish 
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received neo-adjuvant radiochemotherapy (50.4 Gy + 5FU) and 
had a poor clinical outcome (RCPath B & C) compared with patients 
who received neo-adjuvant radiochemotherapy with good clinical 
outcome (RCPath A; *p = 0.0061; Mann–Whitney U Test; Bonferroni 
corrected significance level α = 0.0125)
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the importance of calnexin in colorectal cancer cell sur-
vival and responsiveness to 5FU-based chemotherapy.
The rapid proliferation of tumour cells requiring 
increased protein translation coupled with the inad-
equate blood supply has been suggested to lead to ER 
stress and activation of the UPR [8]. A tumour cell’s abil-
ity to tolerate ER stress may account for its capacity to 
grow under adverse conditions and to resist current 
chemotherapeutic regimens. The ER resident chaper-
one GRP78, which plays a key role in sensing misfolded 
proteins and activating the UPR, has been shown to be 
up regulated in a variety of cancer cell lines and human 
specimens including breast, lung, liver and prostate can-
cer [7, 12]. However, we demonstrate that the expression 
of GRP78 was low in both tumour and matched normal 
tissue in our colorectal cancer patient samples and the 
expression levels of GRP78 failed to correlate with dis-
ease stage or clinical outcome. In contrast to our findings, 
other studies have demonstrated that the level of GRP78 
positively correlated with tumour progression in primary 
human breast [13], liver [14] and melanoma [15] tumour 
tissue. Interestingly, a study by Hardy et al. [16] showed 
that the localisation of GRP78 within colon cancer cells 
was crucial to their tumourigenicity with cells expressing 
GRP78 in the ER but not on the cell surface being highly 
proliferative and capable of inducing liver metastasis in 
a human metastatic colorectal carcinoma model in mice 
[16]. While we did not detect differences in the subcel-
lular localisation of calnexin by immunohistochemistry 
among good and poor responders, it is possible that the 
localisation of GRP78 and not its overall expression level 
or tumour/normal ratio determines its contribution to 
disease stage or clinical outcome of the patient. This was 
not further analysed in this study as we were not able to 
identify a solely GRP78 specific antibody compatible with 
FFPE samples.
We also demonstrate that the glucose regulated ER 
resident molecular chaperone GRP94 is lowly expressed 
in our colorectal cancer tumour and matched normal 
samples. Previous studies indicate that overexpression 
of GRP94 associated with cellular transformation and 
tumourigenicity in cancer cell lines [17]. In contrast, 
GRP94 is known to elicit anti-tumour immune responses 
in mouse models [18, 19] through its ability to bind and 
present tumour specific antigens [20] and induce matu-
ration of dendritic cells [21]. However, we found no 
evidence that the expression of GRP94 correlated with 
disease stage or clinical outcome in our cohort of CRC 
patients.
Calcium, the universal signaling molecule involved in 
processes such as protein modification, protein folding 
and cell survival and death signaling, is stored in the ER, 
where it is buffered by that calcium binding ER chaper-
ones calreticulin and calnexin. Our data demonstrate 
that an increased tumour/normal ratio of calnexin, but 
not calreticulin, was significantly associated with poor 
clinical outcome in patients that received chemotherapy. 
Calreticulin has been implicated in affecting cell sensitiv-
ity to apoptosis, with calreticulin deficiency lowering ER 
luminal Ca2+ concentrations and protecting cells from 
apoptosis [22] while overexpression of calreticulin sensi-
tizes cells to the induction of apoptosis [22, 23]. Expres-
sion of the calcium binding ER chaperone calnexin has 
been shown to be a good predictor of cell sensitivity to 
ER stress-mediated cell death [24] and to mediate resist-
ance to apoptosis through its caspase-dependent cleav-
age [25]. In the present study, we significantly expand on 
the key role of calnexin in colon cancer cell survival by 
demonstrating that gene silencing of calnexin decreases 
clonogenic cell survival. Furthermore, we show that gene 
silencing of calnexin in combination with 5FU treatment 
significantly increases the percentage of cells undergo-
ing both early (Annexin V+ only cells) and late apoptosis 
(Annexin V+PI+ cells) as well as inducing significant lev-
els of necrosis (PI− only cells and Annexin V+PI+ cells). It 
has been previously demonstrated that cells defective in 
apoptosis undergo autophagy-induced necrotic-like cell 
death as a result of prolonged ER stress [26], which could 
explain the induction of necrosis observed in our study.
CRC patients with tumors exhibiting high microsatel-
lite instability (MSI) were previously shown not to benefit 
from 5FU-based adjuvant chemotherapy [27]. Our find-
ing might suggest that, targeting calnexin in combina-
tion with 5FU treatment might improve overall survival 
among patients with high MSI, since HCT-116 cells are 
known to feature clinical and cytological characteristics 
of CRC patients stratified for high MSI [28].
Conclusions
In summary, this study indicates that the calnexin pro-
tein levels may represent a new indicator of poor clini-
cal outcome of stage II/III colorectal cancer patients who 
received 5FU-based chemotherapy. Furthermore, our 
in vitro studies confirmed the importance of calnexin for 
colorectal cancer cell growth and proliferation and also 
demonstrated that calnexin deficiency could enhance 
responsiveness to 5FU-based-chemotherapy. Together, 
these results suggest a possible role for the calcium bind-
ing chaperone calnexin as a prognostic biomarker in 
stage 2 and 3 colorectal cancer and as a potential thera-
peutic target, which requires further validation in clinical 
and pre-clinical studies.
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